Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Standard Biotools Q3 2026 Results: Turns Profitable, Net Income $13.5M

Standard BioTools reported a net income of $113.8 million for the nine months ended September 30, 2026, primarily driven by a $202.3 million gain on the sale of a business recorded in discontinued operations. However, the company experienced a loss from continuing operations of $57.7 million during the same period, reflecting ongoing restructuring and integration expenses.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue19.419.6
Gross profit10.89.5
Profit before tax-14.9-32.9
Net income13.5-34.7
EPS (diluted, $ a share)$0.03$-0.09

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-0.9%
Gross margin55.9%
Operating margin-102.0%
Source

10-Q filed with the SEC, NASDAQ: LAB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Standard Biotools Inc.: key numbers

Share price
$0.6210Close, Nov 16
Market cap
$245M
Shares outstanding
394.79MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Standard Biotools Inc.

All →
4:37 PM ET 8-K
M&A Deal

Standard Biotools M&A Deal with Treeline Biosciences, Inc.

Standard BioTools Inc. provided a status update regarding its pending acquisition of Treeline Biosciences, Inc., specifically addressing stockholder litigation and demand letters. To avoid potential business delays and moot disclosure claims, the company issued supplemental disclosures to its definitive proxy statement ahead of the special meeting of stockholders scheduled for November 19, 2026.

Counterparty
Treeline Biosciences, Inc.
5:36 PM ET Form 4
Insider Buying

Standard Biotools Director Thomas D. Carey Buys $46.9K of Stock

Thomas D. Carey, Director, bought 75,000 shares of Standard Biotools Inc. at $0.6253 a share, worth $46.9K in total on Nov 5, 2026. Shares held after the trade: 419,456 (+21.8%).

Value
$46.9K
Shares
75,000
Price
$0.6253
Role
Director
Holding change
+21.8%
Trade date
Nov 5, 2026
8:23 AM ET 8-K
Divestiture

Standard Biotools Divestiture to Archimed

Standard BioTools Inc. completed the sale of its Microfluidics business to healthcare investment firm ARCHIMED. The divested business will now operate as a standalone independent entity named Biomark Scientific, focusing on high-throughput genomic profiling and microfluidics technology.

Counterparty
ARCHIMED
4:17 PM ET 8-K
Divestiture

Standard Biotools Divestiture to Archimed

Standard BioTools Inc. has entered into a definitive agreement to sell its Microfluidics business to ARCHIMED, a healthcare-focused investment firm. The transaction is expected to close in approximately 30 days and represents a strategic action to streamline the company's portfolio. Financial terms of the divestiture were not disclosed in the filing.

Counterparty
ARCHIMED
5:28 PM ET 8-K
Divestiture

Standard Biotools Divestiture to Element Biosystems, LLC for $5.5M

Standard BioTools terminated its previous agreement with Multiplex Bio and entered into a new definitive agreement to sell its mass cytometry business to Element Biosystems for $5.5 million in cash. The board determined the unsolicited offer from GMT Venture was a superior proposal, as it provides higher cash proceeds and eliminates a previously required $10 million working capital loan. The divestiture is expected to close by the end of 2026, concurrently with the company's pending merger with Treeline Biosciences.

Value
$5.5M
Counterparty
Element Biosystems, LLC (subsidiary of GMT Venture Partners, LLC)

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.